Regulatory transparency in Good Manufacturing Practice (GMP) oversight is entering a period of structural change, driven by increasing expectations from regulators, industry stakeholders, and the broader healthcare ecosystem.
The Therapeutic Goods Administration (TGA) has commenced a public consultation on a proposal to increase transparency regarding Good Manufacturing Practice (GMP) inspection outcomes for manufacturers of pharmaceutical products supplied to Australia.
GLP, GCP, and GMP represent a structured progression of regulatory expectations aligned
Mastering data integrity and Good Documentation Practice is essential for maintaining regulatory compliance and ensuring scientific validity in therapeutic goods development and manufacturing. These principles form the backbone of trustworthy data systems and are essential for demonstrating control, traceability, and reproducibility.